Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
BHVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.80 - $59.53
Previous CloseN/A
Volume146.24K
Average Volume (3M)1.04M
Market Cap
$2.91B
Enterprise Value$4.37B
Total Cash (Recent Filing)$99.13M
Total Debt (Recent Filing)$36.58M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
May 09, 2025EPS Estimate
-1.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.39
Shares Outstanding102,065,000
10 Day Avg. Volume993,466
30 Day Avg. Volume1,040,478
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.98
Forecast
1Y Price Target
$63.33Price Target Upside121.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe impressive 80-84% IgG reduction with BHV-1300 dosing is seen as an attractive base case scenario ahead of the Graves' Phase II launch.
Product DevelopmentBHV-1300 was well tolerated with no safety signals, particularly regarding liver toxicity, which is a positive sign for investors.
Regulatory ApprovalThere is increasing confidence in the likelihood of FDA approval for troriluzole in SCA, which is seen as a potential catalyst for the company.
Bears Say
Clinical Trial ResultsBHV-7000 Ph2 data was negative as it failed to reach statistical significance in bipolar mania, leading to its removal from the model.
Regulatory ChallengesThe SCA approval is far from derisked as the drug has previously received a CRL due to failure in the original placebo-controlled trial.
Research And DevelopmentBiohaven has a high cash burn rate and an arguably overbroad R&D program, making the stock look expensive for its current state.
---
Ownership Overview
14.72% Insiders
23.97% Mutual Funds
31.49% Other Institutional Investors
15.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $26.80 and its highest was $59.53 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $2.91B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is May 09, 2025 which is in 45 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Mar 03, 2025. The company reported -$1.85 earnings per share for the quarter, missing the consensus estimate of -$1.575 by -$0.275.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -1.7.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 102,065,000 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$1.85 in its last earnings report, missing expectations of -$1.575. Following the earnings report the stock price went down -13.771%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
---
Biohaven Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.33 (121.90% Upside)
$63.33 (121.90% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 878.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.92%
12-Months-Change
Fundamentals
Return on Equity
-198.83%
Trailing 12-Months
Asset Growth
19.85%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. (BHVN) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for neurological and neuropsychiatric diseases. The company operates in the healthcare sector and specializes in addressing unmet medical needs within the central nervous system (CNS) disorders. Biohaven's core products include FDA-approved treatments for migraine and other CNS conditions, leveraging its proprietary platforms and extensive research capabilities.
---
BHVN Stock 12 Month Forecast
Average Price Target
$63.33
▲(121.90% Upside)
Technical Analysis
Best Analysts Covering BHVN
1 Year
1 Year Success Rate
9/19 ratings generated profit
1 Year Average Return
+40.96%
reiterated a buy rating last month
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +40.96% per trade.
---